STEVENSON, Md., April 09, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ohr securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s lead product, Squalamine, would not produce vision improvements and was commercially not viable.
According to the complaint, following a January 5, 2018 report that topline data from its MAKO study did not meet its primary efficacy endpoint, the value of Ohr shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Ohr securities purchased on or after June 24, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 



